Ligand Pharmaceuticals (LGND) Short term Debt (2011 - 2023)

Ligand Pharmaceuticals has disclosed Short term Debt across 9 years of filings, most recently posting $76.8 million for Q1 2023.

• Short term Debt for Q1 2023 came in at $76.8 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2023 was $76.8 million (changed N/A YoY), and the FY2022 annual result was $76.7 million, changed N/A from the prior year.
• Short term Debt came in at $76.8 million for Q1 2023 at Ligand Pharmaceuticals, roughly flat from $76.7 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $115.0 million in Q2 2022 to a low of $18.7 million in Q1 2019.
• The 3-year median for Short term Debt is $76.6 million (2022), against an average of $65.1 million.
• Peak annual rise in Short term Debt reached 87.12% in 2019, while the deepest fall reached 91.77% in 2019.
• Ligand Pharmaceuticals' Short term Debt stood at $27.1 million in 2019, then jumped by 183.14% to $76.7 million in 2022, then climbed by 0.12% to $76.8 million in 2023.
• The last three Short term Debt figures came in at $76.8 million (Q1 2023), $76.7 million (Q4 2022), and $76.6 million (Q3 2022), per Business Quant data.